A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors
Status:
Completed
Trial end date:
2021-02-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate whether there are no clinically significant
pharmacokinetic effects of concomitant ramucirumab (IMC-1121B) on paclitaxel by investigating
the pharmacokinetics (PK) of each in participants with advanced malignant solid tumors.
Part A of this study will investigate the potential of concomitant ramucirumab (IMC-1121B) to
affect the pharmacokinetics of paclitaxel. Part B of this study will investigate the
pharmacokinetics of ramucirumab (IMC-1121B) as monotherapy.